BioMarin Files Amicus Financials and Pro Forma Data for $5.3B Acquisition
BMRN sits 20% above its 52-week low of $49.259.
Summary
BioMarin filed audited Amicus financials and pro forma combined data for its $5.3 billion acquisition, revealing a pro forma net loss of $205.9 million for 2025 due to acquisition-related amortization and interest costs.
Key Events · M&A and Partnerships · BMRN
-
Amicus Audited Financials Filed
Amicus had $634.2 million in net product sales in 2025, a net loss of $27.1 million, and an accumulated deficit of $2.8 billion as of December 31, 2025.
-
Pro Forma Combined Loss of $205.9M
The unaudited pro forma combined statement of operations for 2025 shows a net loss of $205.9 million, driven by $390.3 million in additional intangible asset amortization and $180.6 million in incremental interest expense from acquisition debt.
-
Transaction Value and Financing Details
Total transaction value was approximately $5.3 billion, funded by $3.65 billion in new debt (term loans and senior notes) and $1.84 billion in cash and liquidated investments.
-
Intangible Assets Valued at $4.75B
Acquired intangible assets were preliminarily valued at $4.75 billion, including $3.0 billion for Galafold and $1.45 billion for Pombiliti + Opfolda, with amortization periods of 11 and 12 years respectively.
Analysis · BMRN · Life Sciences
This amendment delivers the first detailed look at the financial impact of BioMarin's $5.3 billion acquisition of Amicus. The pro forma combined statements reveal a net loss of $205.9 million for 2025, driven by $390 million in new intangible amortization and $181 million in incremental interest expense from the $3.65 billion debt package. The audited Amicus financials show a company with $634 million in revenue but a $2.8 billion accumulated deficit. The deal was funded with $3.65 billion in new debt and $1.84 billion in cash, significantly leveraging BioMarin's balance sheet. Investors now have the numbers to assess whether the acquisition's cost and integration risks are justified by the combined entity's prospects.
At the time of this filing, BMRN was trading at $59.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.4B. The 52-week trading range was $49.26 to $66.28. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.